Broadfin Capital’s Raptor Pharmaceutical RPTP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
– Sell
-664,800
Closed -$5.96M – 78
2016
Q3
$5.96M Sell
664,800
-5,785,200
-90% -$41.1M 0.53% 48
2016
Q2
$34.6M Sell
6,450,000
-550,000
-8% -$2.82M 3.37% 8
2016
Q1
$32.2M Buy
7,000,000
+4,587,005
+190% +$18.4M 3.11% 8
2015
Q4
$12.5M Buy
2,412,995
+1,000,000
+71% +$5.8M 0.77% 33
2015
Q3
$8.55M Buy
1,412,995
+93,112
+7% +$1.14M 0.48% 54
2015
Q2
$20.8M Buy
+1,319,883
New +$16M 1.12% 21
2015
Q1
– Sell
-15,558
Closed -$164K – 98
2014
Q4
$164K Buy
+15,558
New +$152K 0.01% 75

Broadfin Capital's RPTP Position: Q4 2016 in Review

Broadfin Capital sold out of Raptor Pharmaceutical (RPTP) in Q4 2016, closing a stake of 664,800 shares — an estimated $5.96M sold.

Broadfin Capital first reported a position in RPTP in Q4 2014 and held it in 7 quarters. The position peaked at $34.6M in Q2 2016. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

  • Broadfin Capital reported no remaining Raptor Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • Broadfin Capital sold 664,800 Raptor Pharmaceutical shares in Q4 2016, an estimated $5.96M.
  • Broadfin Capital first reported a position in Raptor Pharmaceutical in Q4 2014 and held it in 7 quarters.
  • Broadfin Capital's Raptor Pharmaceutical position peaked at $34.6M in Q2 2016.
  • 0 funds tracked by Wall St. Rank held Raptor Pharmaceutical as of Q4 2016.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.